<p>(<b>A</b>) Myocytes were exposed to various concentrations of H<sub>2</sub>O<sub>2</sub> for 90 min and viability was assessed by MTT uptake. Data are the mean from three experiments. ARVM were exposed to H<sub>2</sub>O<sub>2</sub> in concentrations ranging from 10 to 1000 µM H<sub>2</sub>O<sub>2</sub>. (<b>B</b>) Adult cardiomyocytes treated with 1mM H<sub>2</sub>O<sub>2</sub> resulted in a 34±2% decrease in viability (‡p<0.001 vs. control) as measured by MTT assay. APN pretreatment (30µg/mL), before H<sub>2</sub>O<sub>2</sub> exposure, increased cell viability by 19±4% (**p<0.01 vs. H<sub>2</sub>O<sub>2</sub>-treated).</p
